Krystal Biotech announces sale of PRV for $100M

Krystal Biotech announced that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher, PRV, for $100 million. The Company was awarded the PRV following the U.S. Food and Drug Administration accelerated approval of VYJUVEKTM for the treatment of recessive or dominant dystrophic epidermolysis bullosa for patients 6 months of age and older. Under the Rare Pediatric Disease Priority Review Voucher Program, the FDA awards priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria.